The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Revvity Inc is $120.00, about 4.1% above its August 3 closing price of $115.22
The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 16 three months ago
